1 Oct 2019 18:06
Director/PDMR Shareholding and Additional Listing
October 1, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that on September 28, 2019 1,626 Conditional Share Awards were exercised by Alistair Gray, Non-Executive Director of the Company, at a price of 5p per share. Following this exercise, Alistair Gray is interested in 1,626 ordinary shares, being
The Company also announces it has today issued and allotted 1,626 new ordinary shares of 5p each ("New Ordinary Shares") following this exercise of Conditional Share Awards under the 2018 Non-Employee Long Term Incentive Plan. Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on October 7, 2019. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 78,325,653. The Company holds no shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |||||
a) | Name | Alistair Gray
| ||||
2. | Reason for the notification | |||||
a) | Position / status | Non-Executive Director
| ||||
b) | Initial notification / Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Silence Therapeutics plc
| ||||
b) | LEI | 213800SSURRJBX85SQ91
| ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares in Silence Therapeutics plc
ISIN for Silence Therapeutics plc Ordinary Shares: GB00B9GTXM62
| ||||
b) | Nature of the transaction | Exercise of share options over Ordinary Shares in Silence Therapeutics plc
| ||||
c) | Prices(a) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
1,626 Ordinary Shares £81.30 | ||||
e) | Date of the transaction | 28 September 2019
| ||||
f) | Place of the transaction | Outside a trading venue
| ||||
Enquiries:
Silence Therapeutics plc Dr David Horn Solomon, Chief Executive Officer
| Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
US IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
| Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and
delivery systems are designed to improve the stability of our molecules and enhance effective delivery
to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
For more information, please visit: https://www.silence-therapeutics.com/